Adage Capital Partners Gp, L.L.C. Immunovant, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51 Billion
- Q1 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Immunovant, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 100,000 shares of IMVT stock, worth $2.64 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
100,000
Previous 1,331,780
92.49%
Holding current value
$2.64 Million
Previous $56.1 Million
94.24%
% of portfolio
0.01%
Previous 0.12%
Shares
8 transactions
Others Institutions Holding IMVT
# of Institutions
238Shares Held
62.9MCall Options Held
1.46MPut Options Held
546K-
Vanguard Group Inc Valley Forge, PA6.48MShares$171 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.48MShares$118 Million0.0% of portfolio
-
State Street Corp Boston, MA3.64MShares$96.1 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.96MShares$78.2 Million2.01% of portfolio
-
Armistice Capital, LLC New York, NY2.16MShares$57.1 Million0.95% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.41B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...